08:26 AM EST, 12/18/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Wednesday said two abstracts highlighting its lead candidate pelareorep's potential in treating gastrointestinal cancers will be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.

"We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer. Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer," said Oncolytics chief medical officer Tom Heineman. "This offers the promise of delaying disease progression and improving survival in patients with these devastating diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients."

Oncolytics was last seen down US$0.01, to US$0.76, in U.S. pre-market trading.